Holen Sie sich die Stockscreener-App
30.33
0.10%
0.03
Vorhandelsmarkt:
30.59
0.26
+0.86%
Schlusskurs vom Vortag:
$30.30
Offen:
$30.4
24-Stunden-Volumen:
429.78K
Relative Volume:
0.89
Marktkapitalisierung:
$1.41B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.31M
KGV:
-6.8001
EPS:
-4.4602
Netto-Cashflow:
$-160.59M
1W Leistung:
-0.72%
1M Leistung:
+8.83%
6M Leistung:
+31.24%
1J Leistung:
+19.32%
1-Tages-Spanne:
$29.13
$30.81
1-Wochen-Bereich:
$29.13
$31.36
52-Wochen-Spanne:
$16.10
$33.62
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
30.33 | 1.41B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
AVBP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsTangible Book Value - newsline.com
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors - TipRanks
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com - Investing.com Canada
Why Is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Down Today? - Meyka
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data - TipRanks
AVBP Q1 2026 Earnings: EPS Misses Estimates as Stock Surges 11% on Pipeline OptimismShare Dilution Risk - The Legal Advocate
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities - Moomoo
ArriVent Biopharma assumed with a Buy at Truist - TipRanks
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
ArriVent BioPharma (AVBP) Surges 12%: Key Levels to WatchJurik MA - newsline.com
(AVBP) Risk Channels and Responsive Allocation - Stock Traders Daily
ArriVent BioPharma (AVBP) Eases 1.68%; Support at $26.1 in Focus After Sector HeadwindsResistance Breakout Stocks - The Legal Advocate
ArriVent BioPharma (AVBP) Slips 1.68% Amid Sector Rotation – Key Support at $26.1 HoldsUndervalued Stocks - newsline.com
ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser
Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada
B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent delays Phase 3 trial to mid-2026 but extends cash runway to Q4 2027, reducing funding risk. - Pluang
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained - TipRanks
ArriVent BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering By Investing.com - Investing.com Australia
ArriVent BioPharma Updates At-The-Market Equity Offering Program - TipRanks
Arrivent Biopharma Enters Open Market Sale Agreement For Offer And Sell Common Stock Up To $250 MillionSEC Filing - TradingView
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering - Investing.com UK
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility - Stock Titan
ArriVent BioPharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ArriVent BioPharma Reports First Quarter 2026 Financial Results - The Manila Times
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress - Stock Titan
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress - Stock Titan
ArriVent Phase 3 and Phase 1 cancer trials backed by $326M through 2027 - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - Yahoo Finance
ArriVent BioPharma Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance - BioWorld News
FDA clears new dual-target cancer drug for ovarian, endometrial trial - Stock Titan
Liquidity Mapping Around (AVBP) Price Events - Stock Traders Daily
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma - Stock Titan
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital - MarketBeat
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):